ArticleMedComm2026

Triple HER2 Blockade With Trastuzumab, Pertuzumab, and Pyrotinib Versus Dual HER2 Blockade in the Neoadjuvant Treatment of HER2-Positive Breast Cancer: A Randomized, Phase II Study.

Jiahui Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.